In comparison to many other therapeutic fields, the discovery of new cardiovascular medications is relatively restricted, despite the unmet medical requirements in the prevention and treatment of cardiovascular disorders. An appealing strategy for the therapy of cardiovascular disease, is therapeutic targeting of RNAs.
Many antisense oligonucleotides and small interfering RNAs have been used in the clinical application of RNA-based treatments over the past ten years, and several have received commercialization approval. Additionally, lncRNA-based therapies are attracting interest, and miRNA inhibitors are undergoing clinical development. Such strategies will make it possible to develop a new method for "undrugable"; targets, but they will also probably have a large clinical impact by making treatment regimens considerably easier to implement than with current medicines. Leveraging academic research and collaborations with industry to identify novel therapeutic targets through pre-clinical development and innovate the delivery would provide a positive path forward in clinical application of nucleic acid-based therapies in cardiovascular diseases.
The main objective of this Research Topic is to showcase manuscripts that have both a strong basic research background and a clear translational potential in cardiovascular diseases. With that in mind, we welcome reviews, original research or methodology articles in this research field that offer great impact and therapeutic potential.
Areas of interest include but are not limited to:
1) The development of novel RNA therapeutics towards cardiovascular disease.
2) The exploitation of various RNA-based therapies in cardiometabolic disease.
3) Clinical and pre-clinical studies.
4) RNA-based therapy delivery methods.
5) Novel research technologies and methods.
In comparison to many other therapeutic fields, the discovery of new cardiovascular medications is relatively restricted, despite the unmet medical requirements in the prevention and treatment of cardiovascular disorders. An appealing strategy for the therapy of cardiovascular disease, is therapeutic targeting of RNAs.
Many antisense oligonucleotides and small interfering RNAs have been used in the clinical application of RNA-based treatments over the past ten years, and several have received commercialization approval. Additionally, lncRNA-based therapies are attracting interest, and miRNA inhibitors are undergoing clinical development. Such strategies will make it possible to develop a new method for "undrugable"; targets, but they will also probably have a large clinical impact by making treatment regimens considerably easier to implement than with current medicines. Leveraging academic research and collaborations with industry to identify novel therapeutic targets through pre-clinical development and innovate the delivery would provide a positive path forward in clinical application of nucleic acid-based therapies in cardiovascular diseases.
The main objective of this Research Topic is to showcase manuscripts that have both a strong basic research background and a clear translational potential in cardiovascular diseases. With that in mind, we welcome reviews, original research or methodology articles in this research field that offer great impact and therapeutic potential.
Areas of interest include but are not limited to:
1) The development of novel RNA therapeutics towards cardiovascular disease.
2) The exploitation of various RNA-based therapies in cardiometabolic disease.
3) Clinical and pre-clinical studies.
4) RNA-based therapy delivery methods.
5) Novel research technologies and methods.